Pivotal Bioventure Partners Investment Advisor 13F annual report
Pivotal Bioventure Partners Investment Advisor is an investment fund managing more than $130 billion ran by Robert Hopfner. There are currently 10 companies in Mr. Hopfner’s portfolio. The largest investments include Vaxcyte and Inozyme Pharma, together worth $79.9 billion.
$130 billion Assets Under Management (AUM)
As of 6th August 2024, Pivotal Bioventure Partners Investment Advisor’s top holding is 793,036 shares of Vaxcyte currently worth over $59.9 billion and making up 46.0% of the portfolio value.
Relative to the number of outstanding shares of Vaxcyte, Pivotal Bioventure Partners Investment Advisor owns more than approximately 0.1% of the company.
In addition, the fund holds 4,494,851 shares of Inozyme Pharma worth $20 billion, whose value fell 4.3% in the past six months.
The third-largest holding is Oculis Holding Ag worth $19.1 billion and the next is Arcutis Biotherapeutics Inc worth $19 billion, with 2,041,108 shares owned.
Currently, Pivotal Bioventure Partners Investment Advisor's portfolio is worth at least $130 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Pivotal Bioventure Partners Investment Advisor
The Pivotal Bioventure Partners Investment Advisor office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Robert Hopfner serves as the Managing Partner at Pivotal Bioventure Partners Investment Advisor.
Recent trades
In the most recent 13F filing, Pivotal Bioventure Partners Investment Advisor revealed that it had opened a new position in
Oculis Holding Ag and bought 1,595,918 shares worth $19.1 billion.
The investment fund also strengthened its position in Vaxcyte by buying
16,997 additional shares.
This makes their stake in Vaxcyte total 793,036 shares worth $59.9 billion.
Vaxcyte dropped approximately 0.1% in the past year.
On the other hand, there are companies that Pivotal Bioventure Partners Investment Advisor is getting rid of from its portfolio.
Pivotal Bioventure Partners Investment Advisor closed its position in Karuna Therapeutics Inc on 13th August 2024.
It sold the previously owned 765,895 shares for $172 million.
Robert Hopfner also disclosed a decreased stake in Exscientia Plc by approximately 0.1%.
This leaves the value of the investment at $3.93 billion and 770,500 shares.
One of the smallest hedge funds
The two most similar investment funds to Pivotal Bioventure Partners Investment Advisor are Triton Wealth Management, P and Brown Advisory. They manage $130 billion and $130 billion respectively.
Robert Hopfner investment strategy
Pivotal Bioventure Partners Investment Advisor’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 76.2% of
the total portfolio value.
The fund focuses on investments in the United States as
40.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
20% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.13 billion.
The complete list of Pivotal Bioventure Partners Investment Advisor trades based on 13F SEC filings
These positions were updated on August 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
Security | Shares Owned | Value | Allocation |
---|---|---|---|
Vaxcyte, Inc. |
2.19%
793,036
|
$59,882,148,000 | 46.04% |
Inozyme Pharma, Inc. |
68.91%
4,494,851
|
$20,047,035,000 | 15.41% |
Oculis Holding Ag |
Opened
1,595,918
|
$19,071,220,000 | 14.66% |
Arcutis Biotherapeutics Inc |
258.69%
2,041,108
|
$18,982,304,000 | 14.59% |
Exscientia Plc |
0.23%
770,500
|
$3,929,550,000 | 3.02% |
Rallybio Corp |
5.87%
2,404,644
|
$3,222,223,000 | 2.48% |
Vigil Neuroscience Inc |
No change
560,595
|
$2,242,380,000 | 1.72% |
Bolt Biotherapeutics Inc |
No change
1,891,467
|
$1,418,600,000 | 1.09% |
Io Biotech Inc |
Opened
864,197
|
$1,011,110,000 | 0.78% |
Aligos Therapeutics, Inc. |
No change
743,215
|
$260,125,000 | 0.20% |
Karuna Therapeutics Inc |
Closed
765,895
|
$172,273,000 | |
Akouos, Inc. |
Closed
1,794,088
|
$12,128,000 | |
Fusion Pharmaceuticals Inc. |
Closed
1,560,984
|
$4,699,000 | |
No transactions found | |||
Showing first 500 out of 13 holdings |
Hedge funds similar to Pivotal Bioventure Partners Investment Advisor
- Stewart Asset Management
- Lowery Thomas
- Virtus Investment Advisers
- Leibman Services
- John & Kathleen Schreiber Foundation
- Amundi Asset Management Us, Inc
- Triton Wealth Management, P
- Brown Advisory
- Brainard Capital Management
- Zynergyretirementplanning
- Scalar Gauge Management
- Guardian Wealth Management
- Pillar Wealth Advisors
- Star Bank